Research map: Pathogenetic therapy with ivacaftor + tezacaftor + elexacaftor plus ivacaftor: Assessment of efficacy and safety of switching within a single INN in children with cystic fibrosis in the Yaroslavl and Tula regions

Back to the article

Papers in this map

  1. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele · Peter Gordon Middleton · 2019 · 2219 citations · Cited by this paper
  2. Frequency of polymorphic variants of the IFNG (rs2069705) and IL28b (rs12979860) genes depending on the severity of clinical manifestations of Opisthorchis felineus invasion · 2026 · Related
  3. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial · Harry G.M. Heijerman · 2019 · 1424 citations · Cited by this paper
  4. Late therapeutic use of tauractant in infants with bronchopulmonary dysplasia: A retrospective comparative study · 2026 · Related
  5. Тargeted therapy for CF patients with F508del/F508del genotype · E. Amelina · 2019 · 16 citations · Cited by this paper
  6. Clinical significance of hyperammonemia in non-alcoholic fatty liver disease · 2026 · Related
  7. Standards for the care of people with cystic fibrosis (CF) · Kevin W Southern · 2023 · 13 citations · Cited by this paper
  8. Changes in results of a skin test with recombinant TB allergen during preventive chemotherapy in children exposed to TB cases · 2026 · Related
  9. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis · Thomas G. Keens · 2024 · 10 citations · Cited by this paper
  10. Expiratory disproportion index as an additional parameter of clinical assessment in bilateral laryngeal paralysis · 2026 · Related
  11. Using generic drug elexacaftor/tezacaftor/ivacaftor+ ivacaftor in patients with cystic fidosis in routine clinical practice · S. Krasovskiy · 2023 · 9 citations · Cited by this paper
  12. Intestinal endometriosis: Current aspects of pathogenesis, clinical picture, and differential diagnosis (a review of foreign literature) · 2026 · Related
  13. Study of the efficacy and safety of the generic drug ivacaftor + tezacaftor + elexacaftor/ivacaftor (trade name Trilexa®) · Е. И. Кондратьева · 2025 · 6 citations · Cited by this paper
  14. Neurological comorbidities in psoriasis and psoriatic arthritis: Neuropathic pain, cognitive impairment and cerebrovascular risk · 2026 · Related
  15. Elexacaftor/tezacaftor/ivacaftor—real-world clinical effectiveness and safety. A single-center Portuguese study · Kelly Lopes · 2023 · 5 citations · Cited by this paper
  16. Combined therapy for infectious and inflammatory diseases of the upper respiratory tract (clinical observation) · 2026 · Related
  17. Pregnancy and childbirth in a cystic fibrosis patient receiving a generic CFTR modulator: the first clinical case in Republic of Kazakhstan · Y. Kenzhebayeva · 2025 · 4 citations · Cited by this paper
  18. Efficacy of rebamipide in Helicobacter pylori eradication regimens: A review of recent experimental and clinical data · 2026 · Related
  19. History of the use of CFTR modulators in the treatment of cystic fibrosis · Е. И. Кондратьева · 2025 · 2 citations · Cited by this paper
  20. Enterosorbents in the combination therapy of alcohol withdrawal syndrome · 2026 · Related
  21. Experience with the use of the generic drug ivacaftor + tezacaftor + elexacaftor and ivacaftor in an adult patient with cystic fibrosis in clinical practice · З. М. Мержоева · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)